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INTRODUCTION 
 
               Poisoning is a major problem globally and its incidence is rising 
due to rapid industrialization and urbanization. The exact incidence of acute 
poisoning is not known in India because of lack of any central poison 
registry. The toxins involved in acute poisoning cases vary from place to 
place. In western countries, the commonest toxins are medicinal agents. In 
contrast, in India, insecticide, pesticides and rodenticide are the most 
commonly consumed agents in adults. 
Ratol is a rodenticide (rat killer paste) ,it contains yellow phosphorus, 
a severe local and systemic toxin causing damage to gastrointestinal, hepatic, 
cardiovascular, and renal systems. Among these liver is the most commonly 
affected organ and acute liver failure with coagulopathy is the most dreaded 
complication. Other fatal complications are  acute tubular necrosis, hepato-
renal syndrome, hypotension and arrhythmias. 
        Clinical manifestations of yellow phosphorous poisoning has  three 
stages. First stage has gastrointestinal symptoms like nausea and vomiting  in 
the absence of any laboratory abnormalities. Second stage occurs after 24–
48 hours characterised by rising transaminases, although the patient may be 
asymptomatic. In some cases, this progresses to the third stage characterised 
by  acute liver failure with coagulopathy and encephalopathy, which can be 
fatal. 
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          The Role of N acetyl cysteine (NAC) in acetaminophen induced  Acute 
fulminant hepatic failure (ALF) was well established. Additionally some 
studies have shown that NAC may be useful in non-acetaminophen induced 
ALF like yellow phosphorous poisoning  also. These toxins damages the 
liver by depleting  glutathione stores. NAC acts by stimulate the glutathione 
synthesis  and enhances glutathione transferase  activity . other beneficial 
effects of NAC are anti-inflammatory, inotropic and vasodilatory effects 
.Therefore, treatment with NAC, which is inexpensive and relatively safe, 
would be a viable treatment option for patients admitted with yellow 
phosphorous consumption with ALF but those who are not eligible for liver 
transplant. 
         A post-mortem liver biopsy shows hydropic or fatty infiltration of 
hepatocytes, collapsed reticulin framework with fibrosis between the 
hepatocytes  and periportal necrosis suggestive of an acute fulminant 
hepatitis  
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AIMS AND OBJECTIVES 
 
1. To study the prevalence of  yellow phosphorus poisoning in our 
hospital 
2. To evaluate the usefulness of N-Acetyl cysteine in yellow 
phosphorous poisoning 
3. Postmortem findings in liver and kidney 
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REVIEW OF LITERATURE 
 RODENTICIDE 
         Rodenticides for many years have been an important cause of 
significant morbidity and mortality in patients who present to an emergency 
room with deliberate self harm. 
         An annual incidence of 500,000 cases has been reported. . One recent 
study shows Incidence of hospital admission of rodenticide poison in 
tamilnadu is approximately 9%. 
 
        The easy availability of these compounds has made this a problem almost 
impossible to control. Most rodenticides produce their toxic or lethal effects in 
humans mainly by ingestion of a large enough single dose.  Of the different 
classes of rodenticides available, yellow phosphorus is considered a highly toxic 
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compound and it can cause hepatocellular necrosis and fulminant hepatic failure 
in up to 50% of patients.  
 
CLASSIFICATION OF RODENTICIDES 
HIGHLY TOXIC COMPOUNDS 
( LD50   - less than 50mg/kg body weight ) . 
 Thallium, 
 Sodium monofluoroacetate, 
 Strychnine 
 Zinc phosphide, 
 Yellow phosphorus  
 Arsenic 
 
MOERATLY TOXIC COMPOUNDS 
 ( LD50   - more than 500 mg/kg body weight) 
Alpha-naphthyl-thiourea (ANTU)  
 DDT. 
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LOW TOXIC COMPOUNDS  
 ( LD50  -  between 500 and 5,000 mg/kg body weight) 
 Red squill, 
 Norbomide   
Anticoagulant - warfarin  
   
Commonly available preparations are 
Rat killer powder – barium ,arsenic 
Rat killer cake -     anticoagulants like warfarin and  related    
 compounds ,coumarins 
Rat killer paste -     yellow phosphorous ,zinc phosphide Rat killer spray 
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YELLOW PHOSPHOROUS  
  GENERAL PROPERTIES 
           Also called as white phosphorous 
          Translucent appearance 
           It has garlic like odour and taste 
           It is highly reactive 
           It is soft waxy solid 
           Luminous in the dark 
           Ignition temperature is low( 303k) so burns  easily in air 
           Burns easily in cl2 
           Highly toxic 
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YELLOW PHOSPHOROUS (YP)– RAT KILLER PASTE(RATOL ) 
POISONING  
         Commonly available as 3% yellow phosphorous  
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MODE OF POISONING 
           Suicidal 
           Accidental  
LETHAL DOSE 
            More than 1mg/kg 
      MECHANISM OF ACTION 
           YP is a protoplasmic poison ,it causes multi organ damage due to 
uncoupling of oxidative phosphorylation  
         After ingestion  YP is rapidly absorbed through the intestinal tract and   
phosphorous remains stable in the gut for longer period because it  has more 
water content and low oxygen tension  . After absorbtion 69% to 73% of the total 
ingested dose concentrates in the liver , some amount  of YP  reaches  the brain, 
striated muscle, and the kidneys also. peak level is reached 2 to 3 hours after of 
toxic oral ingestion.so liver is most vulnerable organ to damages occur. 
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Yellow phosphorous 
↓ 
Phosphoric acid 
↓ 
Exothermic reaction 
↓ 
Direct tissue damage due to production of free radicals 
 
CLINICAL MANIFESTATION 
        The course of events following yellow phosphorus poisoning has three 
stages. 
FIRST STAGE:     (first 24 hours) 
        May be asymptomatic  or 
        Burning pain in the throat and abdomen 
        Nausea ,vomiting  diarrhoea and severe abdominal pain 
        Laboratory values are normal . 
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SECOND STAGE : STAGE OF HEPATITIS (24 TO 48 HOURS) 
         Patient  may be asymptomatic. 
         AST & ALT are elevated 
         Haematological abnormalities are present 
THIRD STAGE : STAGE OF ACUTE LIVER FAILURE 
         Only  few cases are progresses to the third stage 
         Systemic toxicities are present 
GASTROINTESTINAL SYSTEM 
                Prolonged vomiting and diarrhoea 
                Features of  acute fulminant hepatic failure 
                              Liver tenderness and enlargement 
                              Hematemesis and melena due to coagulopathy 
                              Jaundice and pruritus 
                   Hepatorenal syndrome 
                   Marked elevation of transamiases, alkaline phosphatases and    
prothrombin time 
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RENAL SYSTEM 
                 Acute tubular necrosis   
                 Acute renal failure 
CARDIOVASCULAR SYSTEM 
                 Hypotension and tachycardia 
                 Arrhythmias 
                 Acute pulmonary edema 
                 Myocardial injury 
                 Cardiogenic shock  
Alteration in ECG such as  inverted  T  waves,  changes  in  QRS complex,  
tachycardia,  arrhythmias  and  decreased  ventricular  contractility  has been  
reported 
HEAMATOLOGICAL 
                 Direct bone marrow suppression  mainly selective myeloid series 
suppression causes leucopenia  with preserved normoblastic erythroid 
maturation, normal megakaryocytes, lymphocytes, and plasma cells 
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CENTRAL NERVOUS SYSTEM 
               Confusion  
               Psychosis 
               Hallucinations  
               Coma 
 
TOXIC HEPATITIS 
COMMON CAUSES 
1)Alcohol. 
             Large amount of alcohol drinking over many years can lead to alcoholic 
hepatitis 
2)Over-the-counter pain relievers.  
              Self medication mainly analgesics  such as "acetaminophen , aspirin, 
ibuprofen  and naproxen  can damage the liver especially if taken frequently or 
combined with alcohol". 
3)Toxins and chemicals 
               Like yellow phosphorous 
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4)Prescriped drugs.  
            Some commonly used drugs linked to serious liver injury include the 
statin s, the combination drugs like amoxicillin-clavulanate , phenytoin , 
azathioprine  , ketoconazole, certain antivirals and anabolic steroids.  
5)Herbal products. 
              Some herbs measured dangerous to the liver include aloe vera, black 
cohosh, cascara, chaparral, comfrey, kava and ephed. 
6)Industrial chemicals.  
              Common chemicals that can cause liver damage include the dry 
cleaning solvent  like carbon tetrachloride,  vinyl chloride ,  paraquat and 
polychlorinated biphenyls . 
 
RISK FACTORS 
1)consumption of over-the-counter pain relievers or certain prescription drugs. 
          "Taking a medication or over-the-counter pain reliever that carries a risk 
of liver damage and increases  risk of toxic hepatitis".  
2)Chronic liver disease.  
            " Having a serious liver disorder such as cirrhosis or nonalcoholic fatty 
liver disease makes  much more susceptible to the effects of toxins". 
18 
 
3)Viral hepatitis.  
            Chronic infection with a hepatitis virus  like hepatitis B, hepatitis C  
makes the  liver more vulnerable. 
4)Aging. 
          Elder person's liver breaks down harmful substances more slowly. This 
means that toxins and their byproducts stay in the body longer.so it causes more 
damage to liver. 
5)Drinking alcohol. 
              Consumption alcohol while taking drugs or certain herbal supplements 
increases the risk of toxicity. 
6)Female sex. 
             Womens have slowely metabolising capacity than men , so their livers 
are more exposed to higher blood concentrations of harmful substances for a 
longer time. This also increases the risk of toxic hepatitis. 
7) Genetic mutations 
                Inheriting certain genetic mutations that affect the production and 
action of the liver enzymes that break down toxins may makes  more vulnerable 
to toxic hepatitis. 
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MECHANISMS OF TOXIC HEPATITIS 
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The pathophysiologic mechanisms of hepatotoxicity are  characterized by 
organic and functional damage of the liver. 
 The principal alterations are: 
(1) Disruption of the hepatocyte; 
    Absorbed toxins are covalently  binding  to intracellular proteins ,cause a 
decrease in ATP levels. It lead to disassembly of actin fibrils on the surface 
of the hepatocyte with blistering and rupture of the membrane; 
 
(2) Disruption of the transport proteins;  
    Toxins may affect transport proteins at the canalicular membrane and can 
interrupt bile flow. It also cause  interruption of transport pumps; 
 
(3) Cytolytic T-cell activation: 
    The covalent binding of a toxin to the P-450 enzyme acts as an 
immunogen, activating T cells and cytokines and stimulating a multifaceted 
immune response 
(4)toxin  adducts targeted by CTLs/cytokines 
           migration of these enzyme-drug adducts to the cell surface in vesicles to 
serve as target immunogens for cytolytic attack by T cells, stimulating an 
immune response involving cytolytic T cells and cytokines. 
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  (5)Apoptosis of hepatocytes; 
       The  apoptotic pathways are activated  by the tumor necrosis factor-
alpha receptor of Fas may trigger the cascade of intercellular caspases, 
which results in programmed cell death; 
 Apoptosis occurs by one of two pathways: 
 (1)a deathreceptor pathway;  
 (2) the mitochondrial pathway. 
(6) Mitochondrial disruption 
            Some toxins inhibit the mitochondrial function by by a dual effect on 
both beta-oxidation  and respiratory chain enzymes  by inhibiting the synthesis 
of nicotinamide adenine dinucleotide and flavin adenine dinucleotide, resulting 
in decreased ATP production  causes  lack of aerobic respiration,and 
accumulation of lactate and reactive oxygen species (which may disrupt 
mitochondrial DNA). 
Bile duct injury  - toxic metabolites excreted in bile may cause injury to 
the bile duct epithelium  
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MITOCHONDRIAL DYSFUNCTION 
Various endogenous and exogenous substances impairs the mitochondrial 
β-oxidation to cause micro-vesicular steatosis through oxidative stress and 
damage to mitochondrial proteins, lipids, and DNA. In humans, these oxidative 
lesions cause mitochondrial DNA (mtDNA) deletions. 
                   mtDNA is a circular, double-stranded molecule. Each cell contains      
many copies of this DNA. MtDNA is extremely sensitive to oxidative damage 
.because  it is proximity to the inner membrane (the main cellular source of 
ROS), the absence of protective histones, and incomplete repair mechanisms in 
mitochondria 
 
OXIDATIVE STRESS 
The oxidative damage caused by free radicals is thought to be a basic 
mechanism underlying  the hepatotoxicity produced  by toxins. 
Oxidative stress develops when there was an imbalance between the pro-
oxidant and antioxidant ratio, leading to the generation of ROS. Toxins are 
known to modulate antioxidant defensive systems and cause oxidative damage 
in organisms by ROS production. 
Oxidative damage accumulates more in mitochondria than in the rest of 
the cells because electrons continually leak from the respiratory chain to form 
damaging ROS . 
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ROS, such as hydrogen peroxide (H2O2), superoxide anion O2-, and 
hydroxyl radical (OH•) at supranormal levels, can react with biological 
macromolecules potentially leading to enzyme inactivation, LPO, DNA damage 
and cell death, but at low concentrations their effects are less pronounced. 
These free radicals are capable of damaging many cellular components 
such as DNA, proteins and lipids. 
 
 
GLUTATHIONE 
Glutathione (GSH) is an important antioxidant . It is capable of preventing 
damage to important cellular components caused by reactive oxygen species 
such as free radicals, peroxides, lipid peroxides, and heavy metals. "It is a 
tripeptide with a gamma peptide linkage between the carboxyl group of the 
glutamate side chain and the amine group of cysteine, and the carboxyl group of 
cysteine is attached by normal peptide linkage to a glycine". 
Thiol groups are reducing agents. "Glutathione reduces disulfide bonds 
formed within cytoplasmic proteins to cysteines by serving as an electron donor. 
In the process, glutathione is converted to its oxidized form, glutathione disulfide 
(GSSG), also called L-(–)-glutathione". 
Once oxidized, glutathione can be reduced back by glutathione reductase, 
using NADPH as an electron donor. The ratio of reduced glutathione to oxidized 
glutathione within cells is often used as a measure of cellular oxidative 
stress."Glutathione exists in both reduced (GSH) and oxidized (GSSG) states". 
In the reduced state, the thiol group of cysteine is able to donate a reducing 
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equivalent (H++ e−) to other molecules, such as reactive oxygen species to 
neutralize them, or to protein cysteines to maintain their reduced forms. With 
donating an electron, glutathione itself becomes reactive and readily reacts with 
another reactive glutathione to form glutathione disulfide (GSSG). Such a 
reaction is probable due to the relatively high concentration of glutathione in 
cells (up to 7 mM in the liver). 
In healthy cells and tissue," more than 90% of the total glutathione pool 
is in the reduced form (GSH) and less than 10% exists in the disulfide form 
(GSSG)". An increased GSSG-to-GSH ratio is considered indicative of oxidative 
stress 
   
Glutathione has multiple functions: 
1. It maintains levels of reduced glutaredoxin and glutathione peroxidase 
2. It is one of the major endogenous antioxidants produced by the cells, 
participating directly in the neutralization of free radicals and reactive 
oxygen compounds, as well as maintaining exogenous antioxidants such 
as vitamins C and E in their reduced (active) forms. 
3. 3)Regulation of the nitric oxide cycle is critical for life, but can be 
problematic if unregulated. 
4. 4)It is used in "metabolic and biochemical reactions such as DNA 
synthesis and repair, protein synthesis, prostaglandin synthesis, amino 
acid transport, and enzyme activation". Thus, every system in the body 
can be affected by the state of the glutathione system, especially the 
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immune system, the nervous system, the gastrointestinal system, and the 
lungs. 
5.  It has a vital function in iron metabolism.  
6. It has roles in progression of the cell cycle, including cell death.GSH 
levels regulate redox changes to nuclear proteins necessary for the 
initiation of cell differentiation. "Differences in GSH levels also 
determine the expressed mode of cell death, being either apoptosis or cell 
necrosis". Manageably low levels result in the systematic breakage of the 
cell whereas excessively low levels result in rapid cell death 
 
          Systemic bioavailability of orally consumed glutathione is poor because 
the molecule, a tripeptide, is the substrate of proteases (peptidases) of the 
alimentary canal, and due to the absence of a specific carrier of glutathione at the 
level of cell membrane. 
         "Because direct supplementation of glutathione is not always successful, 
supply of the raw nutritional materials used to generate GSH, such as cysteine 
and glycine, may be more effective at increasing glutathione levels".  
Additionally, compounds such as N-acetylcysteine (NAC)  capable of helping to 
regenerate glutathione levels. 
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 DRUG TOXICITY MECHANISM: 
          Two major types of chemical hepatotoxicity have beenrecognized:  
 
(1) direct toxic  
              Direct toxic hepatitis occurs with predictable regularity in 
individuals exposed to the offending agent .It is dose-dependent. The latent 
period between exposure and liver injury is usually short (often several 
hours), although clinical manifestations may be delayed for 24–48 h.  
             Agents producing toxic hepatitis are generally systemic poisons or 
are converted in the liver to toxic metabolites.The direct hepatotoxins result 
in morphologic abnormalities that are reasonably characteristic and 
reproducible for each toxin. 
 
(2) idiosyncratic  
             Idiosyncratic drug reactions can be subdivided into those that are 
classified as hypersensitivity or immunoallergic and those that are 
metabolic-idiosyncratic 
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SIGNS AND SYMPTOMS OF TOXIC HEPATITIS : 
            Jaundice,  
            Pruritus ,  
            Abdominal pain in the right side of the abdomen, 
            Easy fatiguablity, 
            Loss of appetite, 
            Nausea and vomiting,  
             Rash,  
             Weight loss,  
             Dark coloured urine. 
           In acute toxic hepatitis the patient’s condition is similar to viral 
hepatitis and rapidly deteriorates, resulting in marked liver dysfunction, 
encephalopathy and coagulopathy. 
          The features of toxic hepatitis are:  
           Apoptosis of hepatocytes, 
           Ischemic liver injury, 
           Sepsis,  
           Cholestasis. 
           Hepatocyte apoptosis and necrosis, when massive, result in    
fulminant hepatic failure. 
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ACUTE LIVER FAILURE 
DEFINITION 
          The original definition of fulminant hepatic failure by "Trey and 
Davidson in 1959 stipulated an onset of hepatic encephalopathy within 8 
weeks of the first symptoms of illness, in patients without pre - existing liver 
disease"  . 
             A broader definition includes patients with onset of disease to 
encephalopathy of as long as 26 weeks, although the majority of cases are 
of much shorter duration. 
 
CLASSIFICATION OF ACUTE LIVER FAILURE 
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CAUSES OF ACUTE LIVER FAILURE  
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CLINICAL FEATURES 
             The patient with "acute liver failure typically develops non - specifi c 
symptoms such as nausea, vomiting,  malaise, jaundice and signs of hepatic 
encephalopathy, evolving relatively quickly".  
           The liver is often shrunken due to loss of hepatic mass and may be as 
small as 600 g in size (normal approximately 1600g )."Declining hepatocellular 
function impairs synthesis of clotting factors and glucos leading to coagulopathy 
and hypoglycaemia". 
              Metabolic acidosis results from reduced clearance and increased 
production of lactate. Tachycardia, hypotension, hyperventilation and fever may 
occur and signs of the systemic infl ammatory response may be present. 
       Patients with a more gradual onset of hepatic insufficiency (over weeks 
rather than days, and variously called" subfulminant, subacute or late onset") 
infrequently develop cerebral oedema. Ascites, oedema and renal failure are 
more likely in this slowly evolving setting outcome depends on the underlying 
aetiology . Those patients that survive without transplant usually have a complete 
recovery . 
Hepatic e ncephalopathy 
             Hepatic encephalopathy and cerebral oedema with raised intracranial 
pressure (ICP) are hallmarks of acute liver failure. The pathogenesis of hepatic 
encephalopathy is multifactorial and centres on failure of the liver to remove 
toxic, mainly gut - derived, substances from the circulation. Arterial ammonia 
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levels rise and appear to contribute to astrocyte swelling. Levels greater than 150 
to 200 mmol/L have been shown to correlate with cerebral oedema and 
herniation .   
                The onset of encephalopathy is often sudden, may precede jaundice, 
and, unlike chronic liver disease, may be associated with agitation, changes in 
personality,delusions and restlessness. Asterixis may be transient.Fetor 
hepaticus is usually present. 
 
 Pathogenesis of cerebral oedema and potential targets for therapy: 
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TREATMENT: 
In order to optimize survival, one must establish the diagnosis of acute 
liver failure quickly, evaluate the potential aetiologies and therapies, and 
estimate the severity to appropriately identify those that will need 
transplantation.  
King ’ s College Hospital criteria for liver transplantation in acute liver failure 
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DIAGNOSIS OF YELLOW PHOSPHOROUS POISONING 
LAOBORATORY LIVER FUNCTION TEST 
1)ENZYMES 
Liver damage can be of two types:  
(A) Hepatocellular damage (death of liver cells), in which alanine 
aminotransferase and aspartate aminotransferase are altered; 
 (B) Cholestatic damage (bile stasis) with an increase of parameters such as 
alkaline phosphatase and γ-GT. 
        Serum alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) activities are routinely used as clinical endpoints indicative of 
hepatotoxicity.  
         ASTand ALT concentrations begin to rise within 24 hours after an acute 
ingestion and peak at about 72 hours. In severe overdose, transaminase elevation 
can be detected as early as 12-16 hours post-ingestion of yellow phosphorous. 
        ALT is considered to be liver-specific ,elevated serum AST is indicative 
of tissue and cellular damage, but is not specific for hepatotoxicity. As a general 
rule, clinically significant liver injury is often defined as ALT > 3 times the upper 
limit of normal . 
2)SERUM  BILIRUBIN 
Serum bilirubin level will be elevated depending upon the  amount of 
poison consumed ,serial monitoring should be needed. 
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3)PROTHROMBIN TIME/INR  
Prothrombin time (PT) and international normalized ratio (INR) should 
be measured and followed closely. PT is a indicator of impaired hepatic synthetic 
function in the setting of hepatic dysfunction and developing liver failure. 
Abnormal values are also predictors of mortality. 
RENAL FUNCTION TEST 
           Renal function tests ( blood urea,serum creatinine and serum electrolytes 
concentrations) can reveal evidence of co-existing renal failure and hepatorenal 
syndrome.  
           An elevated serum creatinine concentration is also a predictor of 
mortality.  
           Urinalysis showing proteinuria and hematuria may indicate acute tubular 
necrosis. 
SERUM GLUCOSE 
Obtain serum glucose concentration to assess hypoglycemia as the result of 
impaired hepatic gluconeogenesis 
ECG  
Alteration in ECG such as  inverted  T  waves,  changes  in  QRS complex,  
tachycardia,  arrhythmias  and  decreased  ventricular  contractility  has been  
reported 
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ACID BLOOD GAS ANALYSIS 
               Arterial blood gas and serum lactate concentrations should be 
monitored. A pH of less than 7.3 or a lactate concentration greater than 3.5 after 
fluid resuscitation are laboratory indicators predictive of mortality. 
  
SERUM AMMONIA 
              Serum ammonia level should be monitored if patient presented with 
altered mental status or clinical signs of encephalopathy .Some  research shows 
that arterial ammonia concentrations are higher than venous ammonia 
concentrations in a patient with acute liver failure and may be predictive of 
neurologic death. However, in a clinical picture that is consistent with acute 
hepatic dysfunction and encephalopathy, a venous sample may  be considered 
sufficient in the context of other indicators of acute liver failure  
 
Key laboratory findings during the first 3 phases of  hepatotoxicity are : 
        Phase 1: Approximately 12 hours after an acute ingestion, liver function 
studies show a subclinical rise in serum transaminase levels (ALT, AST) 
 
        Phase 2: Serum studies reveal elevated ALT and AST concentrations, PT, 
and bilirubin concentration; renal function abnormalities may also be present 
and indicate nephrotoxicity 
 
         Phase 3: Severe toxicity is evident on serum studies, and include: lactic 
acidosis, prolonged PT or INR, markedly elevated ALT and AST , elevated total 
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bilirubin level of more than 4 mg/dL (primarily indirect), hypoglycemia, and 
hyperammonemia are reported. 
 
RADIOLOGICAL INVESTIGATIONS 
USG ABDOMEN 
                Abdominal ultrasonography is a noninvasive diagnostic tool that may 
reveal  hepatic enlargement or renal abnormalities, as well as inflammatory 
changes of other abdominal organs .     
              Toxic hepatitis is characterized by different degrees of steatosis and 
fibrosis, which can lead to cirrhosis. 
               In USG abdomen , steatosis can be classified as:  
 
(1) light steatosis - presence of slight “bright liver” and no deep attenuation;  
(2) moderate steatosis - presence of mild “bright liver” and with deep 
attenuation; and 
 (3) severe steatosis -  presence of diffusely severe “bright liver” and deep 
attenuation without visibility of the diaphragm 
 
CT BRAIN 
Computed tomography (CT) scanning of the brain should also be 
considered in patients with altered mental status. CT may reveal cerebral edema 
in patients with late presentation and encephalopathy (grade III or IV).  
           Additional neuroimaging with magnetic resonance imaging (MRI) may 
be indicated to further define cerebral changes. 
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LIVER BIOPSY 
             Post-mortem liver biopsy  showscollapsed reticulin framework with 
fibrosis between the hepatocytes showing a bubbly and vacuolated cytoplasm 
suggestive of an acute fulminant hepatitis 
 
TREATMENT 
             As no specific antidote has been identified so far, Supportive 
management is the mainstay of therapy. The possible benefits of N-
acetylcysteine (NAC) in improving the prognosis of patients with yellow 
phosphorus poisoning have been noticed in recent case series, with the best 
results seen among patients in whom NAC was started early in the course of 
illness   
 
 1)GASTRIC LAVAGE 
Using 1:5000 solution of pottasium permanganate –it oxidises 
phosphorous in to phosphoric acid and phosphates ,which are harmless. 
Activated charcoal absorbs the poison  
Stomach wash with 0.2%copper sulphate solution or 0.2 g of copper 
sulphate may be given every 5minutes until vomiting occurs.it cots theparticles 
of phosphorous with a film ofcopper sulphide which is relatively harmless. 
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2) INTRAVENOUS FLUIDS 
3)PROTON PUMP INHIBITORS 
4)ANTIEMETICS 
5)VITAMIN K 
6) N ACETYL CYSTEINE  
7)FRESH FROZEN PLASMA 
           If coagulopathy is present 
8)SYRUP LACTULOSE &BOWEL WASH 
           If pt have features of encephalopathy 
9)MECHANICAL VENTILATION 
           If pt have respiratoy failure or poor GCS 
10) LIVER TRANSPLANTATION  
          Ultimate treatment of acute fulminant hepatic failure not amenable to 
medical treatment is liver transplantation. 
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     N ACETYL CYSTEINE 
                       N acetyl cysteine is a prodrug for L-CYSTEINE , is a precursor 
to the biologic antioxidant glutathione. Hence administration of acetylcysteine 
replenishes glutathione stores. 
 N-acetyl-L-cysteine is soluble in water and alcohol 
             
 
 MECHANISM OF ACTION OF NAC 
             It reduce extra-cellular cystine to cysteine 
    Be a source of SH groups: so 
         It stimulate glutathione synthesis, 
         Enhance glutathione-s-transferase activity, 
         Promote detoxification 
         Act directly on reactive oxidant radicals 
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Mechanisms of Protection I: Preventing Covalent Binding 
 
Mechanisms of Protection II: Scavenging of Reactive Oxygen and Peroxynitrite 
Mechanisms of Protection III: Mitochondrial Energy Substrates 
 NAC has anti inflammatory and inotropic activity 
 
It has vasodilatory effects - it improves microvascular circulation and 
oxygenation. 
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PHARMACOKINETICS 
     Oral bioavailability is 10% 
     Protein binding -50 to 83% 
     Extensively  metabolized in liver; 
     Metabolism by  CYP450 minimal. 
     Urine excretion 22-30%  
     Half-life is 5.6 hours in adults  
 
USEFULLNESS IN YELLOW PHOSPHOROUS POISONING          
         The Role of N acetyl cysteine (NAC) in acetaminophen induced  Acute 
fulminant hepatic failure (ALF) was well established. Additionally some studies 
have shown that NAC may be useful in non-acetaminophen induced ALF like 
yellow phosphorous poisoning  also. 
        If the patient presents less than eight hours after poisoning, then NAC 
significantly reduces the risk of serious hepatotoxicity . 
        If NAC is started more than 8 hours after ingestion, there is a sharp decline 
in its effectiveness because the cascade of toxic events in the liver has already 
begun, and the risk of acute liver necrosis and death increases dramatically. 
         Although acetylcysteine is most effective if given early,some studies 
showed that  it still has beneficial effects if given as late as 48 hours after 
ingestion.  
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DOSSAGE 
          For YP poisoning we use the same dossage protocol of NAC used for 
acetaminophen poisoning.  
         The FDA-approved dosage regimen for oral NAC : 
         Loading  dose of 140 mg/kg, followed by 17 doses, each at 70 mg/kg, given 
every 4 hours. 
         The total duration of the treatment course is 72 hours 
         Available strength of tablet is 600mg 
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*-INTRAVENOUS NAC 
          IV NAC administration depend on the patient's body weight and/or on 
whether the ingestion is acute or chronic. 
          Continuous IV infusion is recommended for acute ingestion, as follows: 
Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) 
and infuse over 1 h 
Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h 
Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h 
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ADVERSE EFFECTS 
       For IV formulations 
                The most commonly reported adverse effects of acetylcysteine are        
                Rash 
                Urticaria, 
                 Itchiness. 
          Up to 18% of patients have been reported to experience anaphylaxis 
reaction, which are defined as rash, hypotension, wheezing, and/or shortness of 
breath. 
          Lower rates of anaphylactoid reactions have been reported with slower 
rates of infusion. 
    For oral formulations  
                 Nausea, 
                 Vomiting, 
                 Rash,  
                 Fever. 
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POSTMORTEM FINDINGS IN YELLOW PHOSPHOROUS 
POISONING 
APPEARANCE OF THE BODY 
            Shows signs of jaundice 
SKIN &MUCOUS MEMBRANE 
            Multiple hemorrhages are seen 
STOMACH&INTESTINES 
           Contents have a smell of garlic and may be luminous 
           Mucous membrane of stomach and intestines are yellowish or greyish-
white in colour and are softened,thickened,inflammed and corroded or destroyed 
in patches. 
LIVER 
           It becomes swollen ,yellow ,soft,fatty and easily ruptured and shows 
marbled appearance 
              Small hemorrages may be seen on the surface 
POSTMORTEM LIVER BIOPSY 
        Hydropic or fatty degeneration of hepatocytes,progress to acute 
parenchymal inflammation with cellular necrosis. 
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         Necrosis mostly involves central ,periportal areas of liver but centrilobular 
or panlobular involvement occurs in some patients. 
KIDNEY 
            Kidneys are large,greasy,yellow and shows hemorrhages on the surface 
BIOPSY 
         Congested vessels and focal areas of calcifications are seen. 
HEART 
          Heartis flabby,pale and shows fatty degeneration 
PULMONARY 
         Fat emboli may be found in the pulmonaryarterioles and cappilaries 
BLOOD 
         It may appear tarry and its coagulability is diminished. 
 
 
 
 
 
 
48 
 
 
 
 
 
MATERIALS AND 
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MATERIALS AND METHODS 
 
STUDY POPULATION: 
• The study was conducted on 25 patients with history yellow phosphorous poison 
(ratol) consumption who fulfill the inclusion and exclusion criteria getting  
admitted at Government Rajaji Hospital & Madurai Medical College during the 
period of  june to september 2017. 
 
• The control group patients are taken from retrospective data obtained in year 
2016 at GRH , who had similar management protocol except for NAC use. 
INCLUSION CRITERIA:  
             All patients admitted with history yellow phosphorous poison(ratol) 
consumption at Government Rajaji Hospital & Madurai Medical College during 
the period of june to september 2017. 
 EXCLUSION CRITERIA:  
1. Patient  who have ingested other substance in addition to yellow 
phosphorous will be excluded 
2. Patients who are known to have preexisting liver disease 
3. Patients with chronic kidney disease 
4. Patients with heart disease 
5. Absconded within 24hrs of admission 
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DATA COLLECTION: 
    Informed consent obtained from all patients to be enrolled for the 
study. In all the patients relevant details will be collected in a predesigned 
proforma. 
            The patients are selected based on history of yellow phosphorous 
poisoning, clinical examinations, biochemical tests and ultrasound abdomen 
,toxicological autopsy findings of expired patients  
STUDY PROTOCOL: 
 DESIGN OF STUDY: 
        Prospective cross sectional hospital based observational study 
 PERIOD OF STUDY: 
      4 MONTHS (June 2017 to september 2017) 
 METHODOLOGY: 
          History wsa taken from patients who consumed yellow phosphorous 
poisoning, about time of consumption, amount of consumption,any prior 
hospital admission and treatment before arrived to our hospital. History 
regarding details and duration of alcohol intake was taken,and history of 
vomiting,abdominal pain ,loose stools, altered sensorium also noted. 
            Clinical examination about  presence of icterus,anemia, edema legs , 
features of encephalopathy, abdominal tenderness was noted during admission. 
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            After stomach wash and initial resuscitation, Loading  dose of 140 mg/kg 
of N Acetyl cysteine was started and then  followed by 17 doses, each at 70 
mg/kg, given 4th hourly.The total duration of the treatment course is 72 hours. 
Time of stomach wash and intiation of N Acetyl cysteine was noted. 
             serial monitoring of vitals and complete blood count ,blood sugar ,urea 
,creatinine, serum bilirubin, AST, ALT, prothrombin time, INR ,urine analysis, 
ECG, USG abdomen was estimated. Post-mortem toxicological findings of liver 
and kidney was noted in all expired patients. 
LABORATORY INVESTIGATIONS: 
Complete blood cuunt, liver function tests including serum bilirubin, 
transaminases, prothrombin time and INR, blood sugar, urea creatinine, serum 
electrolytes.  
COLLABORATING DEPARTMENTS: 
DEPARTMENT OF MEDICAL GASTROENTEROLOGY DEPARTMENT 
OF  BIOCHEMISTRY  
DEPARTMENT OF RADIOLOGY 
DEPARTMENT OF FORENSIC MEDICINE 
DEPARTMENT OF PATHOLOGY  
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ETHICAL CLEARANCE:  
          Clearance obtained 
CONSENT: 
            Individual written and informed consent obtained. 
 STATISTICAL ANALYSIS: 
               All data were entered in Excel 2007 and statistical analysis was 
"performed using the statistical software SPSS 16.0.Data were expressed as 
mean values with standard deviation".  
                For continuous variables "Mann Whitney U-test was performed to find 
the differences between two groups and for categorical variables Pearson’s chi-
square test was performed". Results were defined as statistically significant 
when the P value was less than 0.05. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT: SELF 
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OBSERVATIONS 
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RESULTS AND OBSERVATIONS 
 
 TABLE:1    AGE DISTRIBUTION 
Age in years Study Control 
15-25 14 15 
26-35 7 7 
36-45 4 2 
45-55 0 1 
total 25 25 
mean 26.52 25.72 
 
COMMENTS: 
        Among 50 patients of both group, majority are in the age group of 15 to 
25years.so these young adults are more vulnerable to poisoning with yellow 
phosphorous (ratol).  
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TABLE 2 :GENDER DISTRIBUTION 
Sex Study Control 
Male 10 8 
Female 15 17 
Total 25 25 
COMMENTS: 
        Our studies shows 60%of patients in the study group and 68% of 
patients in the control groups are female sex.so females are more prone for 
poisoning.
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TABLE 3:RELATION TO ALCOHOL CONSUMPTION 
Alcoholic Study Control 
Yes 3 3 
No 22 22 
Total 25 25 
 
COMMENTS: 
         Among 50 patients only 6 persons are chronic alcoholic because 
majority of  poison consumed  persons are in the age group of 15 to25years. 
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 TABLE 4:AMOUNT OF POISON CONSUMPTION 
Amount of poison 
consumed 
Study Control 
<1gms 5 6 
>1gms 20 19 
Total 25 25 
Mean 3.74 2.56 
 
COMMENTS: 
      Calculated  Leathal dose of YP is >1mg/kg.our study also shows 
that,80% of  the admitted patients are consumed more than 1gm of poison  
and has more mortality. 
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TABLE 5:COMPARISON OF PRESENCE OF ICTERUS 
 
Presence Of 
Icterus Study 
Control 
Yes 18 18 
No 7 7 
Total 25 25 
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TABLE 6;COMPARISON OF PRESENCE OF HEPATIC 
ENCEPHALOPATHY 
ENCEPHALOPATHY Study Control 
Yes 5 13 
No 20 12 
Total 25 25 
p value 0.039 Significant 
 
COMMENTS: 
           20% of the patients in the study group has hepatic encephalopathy 
compared to 52% in the control group .so early NAC initiation prevents 
from occurrence of encephalopathy. It is statistically significant (p value is 
0.039). 
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TABLE 7:COMPARISON  OF HYPOTENSION 
 
HYPOTENSION Study Control 
Yes 6 14 
No 19 11 
Total 25 25 
p value 0.043 significant 
 
 
COMMENTS: 
        24% of patients in the study group and 56%in the control group have 
hypotension  ,it shows that early treatment with NAC has beneficial in 
reducing hypotensive complication. It is statistically significant ( p value is 
0.043). 
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TABLE 8:COMPARISON OF OLIGURIA 
 
OLIGURIA Study Control 
Yes 5 13 
No 20 12 
Total 25 25 
p value 0.039 Significant 
 
COMMENTS: 
          20% of patients in the study group and 52%in the control group have 
oliguria.It is statistically significant (p value is 0.039). 
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TABLE 9:COMPARISON OF LEUCOPENIA 
 
 
 
COMMENTS  
          Both group have leukopenia ,but control group(36%) is affected more than 
study group(12%). It is not statistically significant (p value is 0.098). 
 
 
LEUCOPENIA Study Control 
Yes 3 9 
No 22 16 
Total 25 25 
p value 
0.098  Not 
significant 
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TABLE 10 A:LIVER FUNCTION TEST 
LIVER FUNCTION 
TEST 
Study Control 
Elevated 19 18 
Normal 6 7 
Total 25 25 
  
COMMENTS: 
       3/4 of patients in the both group have elevated LFT value,remaining 1/4 of 
patients are probably not consumed poison or very minimal consumption. 
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 TABLE 10B:TIME TO NAC INITIATION: 
             
TIME TO NAC 
INITIATION 
Study 
< 1 day 14 
> 1 day 11 
Total 25 
 
COMMENTS: 
       Among 25 patients ,14 reaches our hospital within 24hrs of  poison 
consumption ,so NAC  initiated early .Remaining  patients are admitted in 
peripheral hospital and refered later after pt had features of toxic hepatitis. 
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TABLE 10 C:RESPONSE TO NAC(RECOVERY) 
 
RESPONSE TO 
NAC(RECOVERY) Study Control 
Yes 17 0 
No 8 25 
Total 25 25 
p value < 0.001  Significant 
 
COMMENTS: 
          Among 25 patients17 have good recovery ,because of earlier treatment 
with NAC,Among their some has features of toxic hepatitis and recovered also. 
It is statistically more significant pvalue is <0.05 ( 0.001). 
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TABLE 10 D:SERUM BILIRUBIN RESPONSE TO NAC 
CASE NO 1ST DAY 3RD DAY 6TH DAY 
C1 1.1 1.5 0.9 
C2 0.9 2.9 1.3 
3 1.2 7.9 1.9 
4 1.1 2.5 1.3 
5 1 2.7 1.2 
6 2.1 5.6 3.1 
C7 5.4 23.9 8.1 
C8 0.8 4.1 1.4 
 
Bilirubin values in mgs 
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TABLE 10 E:LIVER ENZYME (ALT) RESPONSE TO NAC 
CASE NO 1ST DAY 3RD DAY 6TH DAY 
C1 40 39 31 
2 21 118 53 
3 51 213 70 
4 39 139 56 
5 29 105 41 
6 33 71 34 
7 198 720 232 
C8 21 255 63 
ALT values in IU/L 
COMMENTS: 
           In the study group 17 patients have good response to NAC, among  their 
8patiens have elevation of LFT (bilirubin,AST,ALT,prothrombin time) mostly 
in the 3rd and 4th day of admission. That LFT values become near normal on 6th 
or 7th day .   
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TABLE 11:COMPARISON OF RENAL FUNCTION TEST 
 
 
COMMENTS: 
RFT value is elevated in both group, but more in control group(48%) than 
study group(28%). It is statistically not significant (p value is 0.244 ). 
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TABLE 12 :OUTCOME OF THE STUDY 
 
 
COMMENTS 
           In  the study group among 25 yellow phosphorous consumed patients 
8patients (32% )  died  inspite of NAC treatment mostly due to delayed 
admission with features of  acute liver failure. In the control group 17 patients 
(68% ) died . So treatment with NAC REDUCES 50% OF  MORTALITY.It is 
statistically more significant (p value is 0.024 , <0.05 ).  
 
 
OUTCOME Study Control
DEATH 8 17
DISCHARGE 17 8
Total 25 25
p value 0.024  Significant
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POSTMORTEM TOXICOLOGICAL FINDINGS: 
LIVER:  
           Sections from liver shows hepatic parenchyma with hepatocytes arranged 
in trabecular pattern ,hepatocytes shows ballooning degeneration with ground 
glass cytoplasm and fatty degeneration in many areas. Also shows many 
congested blood vessels and hemosiderin laden macrophages.  
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KIDNEY:Section studied from kidney shows renal parenchyma with few 
congested blood vessels,vacuolar degeneration of proximal tubular epithelium 
and focal areas of  Calcifications are seen. 
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DISCUSSION 
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DISCUSSION 
Our study was done to identify the prevalence of yellow phosphorus 
poisoning in our hospital and to evaluate the usefulness of N-Acetyl cysteine in 
yellow phosphorous poisoning  and also study the postmortem findings in liver 
and kidney. 
Out of 50 patients 25 were study group those who were treated with N 
Acetyl cysteine (NAC) and another 25 patients were taken from retrospective 
data collected from those who not treated with NAC. 
Our study showed that most vulnerable age group of yellow phosphorous 
(ratol) poisoning was 15 to 25 years. More than 60% of the victims were females. 
So influence of alcohol is not much significant. Calculated  Leathal dose of YP 
in previous study was  >1mg/kg.This  study also told that,80% of  the admitted 
patients are consumed more than 1gm of poison  and has more mortality.Most 
of the patients were admitted with vomiting, abdominal pain, on 3rd  day pt 
developed icterus, feaure of hepaic encephlopathy, bleeding manifestation, 
hypotension , tachycardia and oliguria ,some patients had respiratory failure 
also.           
          In our study  approximately 20% of the patients in the study group and 
50% in the control group had features of hepatic encephalopathy,hypotension 
and oliguria .These data pointed that earlier admission and treatment with NAC  
prevents from occurrence of above said complications. Both group have 
leukopenia ,but control group(36%) is affected more than study group(12%).  
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                 3/4 of patients in the both group had elevated LFT value,remaining 
1/4 of patients are near normal LFT, probably they not consumed poison or very 
minimal consumption. Among 25 patients ,14 reaches our hospital within 24hrs 
of  poison consumption ,so NAC  initiated early .Remaining  patients are 
admitted in peripheral hospital and refered later after pt had features of toxic 
hepatitis.  
In the study group 17 patients have good response to NAC, among  their 
8patiens have elevation of LFT (bilirubin, AST, ALT,prothrombin time) mostly 
in the 3rd and 4th day of admission. That LFT values become near normal on 6th 
or 7th day due to timely treatment with NAC . It is statistically more significant( 
pvalue is   0.001) .          
In  the study group among 25 yellow phosphorous consumed patients, 
8patients (32% )  died  inspite of NAC treatment mostly due to delayed 
admission with features of  acute liver failure. In the control group 17 patients 
(68% )died . So treatment with NAC REDUCES 50% OF  MORTALITY. It is 
statistically more significant (p value is 0.024 , <0.05 ). 
         A recent study conducted in South India showed that "yellow phosphorus 
was the most common rodenticide used in suicide attempts in the region and 
carried a 30% mortality despite maximal supportive therapy"."The LD50 dose 
in yellow phosphorus poisoning is 10 mg/kg body weight; however, ingestion of 
a dose as low as 100 mg has been seen to result in death". Indicators for poor 
outcome included early elevation of liver transaminases and alkaline 
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phosphatase, more than 10-fold increase in alanine aminotransferase, 
derangement in prothrombin time, metabolic acidosis, and hypoglycemia. These 
individuals usually demonstrate only minimal gastrointestinal symptoms during 
the first 48–72 h but subsequently develop acute liver failure, progressing to 
multi-organ failure and death in severe cases. 
         Another study showed that "who consumed lethal dose of poison, 
presenting early and received NAC, 43% had moderate and 43% had severe 
hepatic injury. Among severe injury, 14% developed fulminant hepatic failure 
[FHF] and died". Among patients "who consumed lethal dose, presenting early 
but not receiving NAC, 33.3% had moderate and 66.7% had severe hepatic 
injury. All severe cases in this group developed FHF with mortality of 100%. 
Patients presenting late after consumption of lethal dose, who receive did not 
NAC developed FHF with mortality of 100%". Patients consuming sub lethal 
dose had 100% survival without hepatic damage. 
          Our study also revealed that 32% of mortality occur in  NAC group 
compared to 68% in control group (those who not received NAC). Eventhough 
guidelines do not exist regarding routine use of NAC in non acetaminophen 
induced ALF, and in hepatic failure due to yellow phosphorous consumption, 
Patients admitted with ALF after phosphorus ingestion have better survival with  
NAC treatment. So  early  admission and initiation of NAC reduces mortality up 
to 50% and better  survival. 
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         " Prevention strategies by restricting access to this poison can be the one 
of the best method to avoid complications. Public as well clinicians should be 
made aware of lethality of inorganic phosphorus in miniscule quantities, and 
regulating the market sale of this compound should be helpful". However, this 
lethal ratol paste is easily available at cheaper costs and accidental poisoning is 
also more common, especially among children. Hence, we call for a ban on 
market sales of ratol paste. 
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CONCLUSION 
 
                   Most patients admitted with history of suicidal consumption of  ratol 
(yellow phosphorous) were young and belonged to poorer socio-economic 
sections.  Mortality was reduced to 50% in the study group  who was admitted 
early and treated with NAC, eventhough they consumed  lethal dose of ratol. 
Therefore treatment with NAC, which is inexpensive and relatively safe, would 
be a viable treatment option for patients admitted with ratol consumption. 
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SUMMARY 
 
        A prospective cross sectional observational study was done at Government 
Rajaji Hospital, Madurai  among 50 yellowphosphorous poison (ratol) consumed 
patients. Study group(25 patients) contains those who were treated with NAC 
,The control group(25 patients) are taken from retrospective data obtained in year 
2016 at GRH , who had similar management protocol except for NAC use. Data 
was collected about timing and amount of poisoning,timing of initiation of 
stomach wash and NAC, clinical and laboratory parameters. Most of the patients 
were young females who consumed more than 1gm of poison(more than lethal 
dose) presented with icterus ,features of hepatic encephalopathy ,hypotension 
,oliguria , and elevated serum bilirubin ,transaminases and prothrombin time. 
Those who were treated with NAC had improvement in both clinically and 
biochemically . Morbidity and Mortality was reduced to 50% in the study group  
who was admitted early and treated with NAC, eventhough they consumed  
lethal dose of ratol. 
 
 
 
∙ 
 
82 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
83 
 
BIBLIOGRAPHY 
1) Mauskar A, Mehta K, Nagotkar L, Shanbag P (2011)Acute hepatic failure 
due to YP ingestion. Indian JPharmacol 43(3): 355–356. 
2) Karanth S, Nayyar V (2003) Rodenticide-induced Hepatotoxicity. JAPI 
51. 
3) Tafur AJ, Zapatier JA, Idrovo LA, Oliveros JW, Garces JC. Bone   
marrow toxicity after yellow phosphorus ingestion. Emerg Med J. 
2004;21:259–60.  
4) Lakshmi CP, Goel A, Basu D. Cholestatic presentation of yellow 
phosphorus poisoning. J Pharmacol Pharmacother. 2014 Jan;5(1):67–9. 
5) McCarron MM, Gaddis GP, Trotter AT. Acute yellow phosphorus   
poisoning from pesticide pastes. Clin Toxicol. 1981;18:693–712.  
6) Smitha Bhat corresponding author1 and Kumar P. Kenchetty  N-Acetyl 
Cysteine in the Management of Rodenticide Consumption — Life 
Saving? JClinDiagnRes. 2015 Jan; 9(1): OC10–OC13. Published online 
2015 Jan 1. Doi :  10.7860 / JCDR / 2015 / 11484.5455 PMCID: 
PMC4347107 
7) Syed IdrisKafeel ,Chandrasekaran VP , Eswaran VP Role Of N – Acetyl 
Cystine In Outcome Of Patients With Yellow Phosphorus Poisoning – An 
Observational Study 
8) Aneesh Basheer, corresponding author 1 SudhagarMookkappan, 1 
Somanath Padhi, 2 and NayyarIqbal  Selective myelosuppression  
following yellow phosphorus ingestion Australas Med J. 2015; 8(1): 19–
84 
 
23. Published online 2015 Jan 31. doi:  10.4066/AMJ.2015.2241 PMCID: 
PMC43211 
9) S Khaja Mohideen, K Senthil Kumar Should ratol paste be banned Year : 
2015  |  Volume : 19  |  Issue : 2  |  Page : 128-129 Department of 
Anaesthesiology and Critical Care, Kauvery Hospitals, Trichy, Tamil 
Nadu, India 
10) Meban Aibor Kharkongor, Ajay Kumar Mishra, K Fibi Ninan, Ramya 
Iyadurai Early use of intravenous N-acetylcysteine in treatment of acute 
yellow phosphorus poisoning Year : 2017  |  Volume : 15  |  Issue : 2  |  
Page : 136-138 Department of Internal Medicine, Christian Medical 
College, Vellore, Tamil Nadu, India 
11) SHIJU K SLEEBA, MIDHUN RAJ, PA KABEER, DIPU K. P. A RARE 
CASE OF YELLOW PHOSPHOROUS POISONING WITH ACUTE 
CHOLESTATIC HEPATITIS, BICYTOPENIA, AND IMPENDING 
HEPATIC FAILURE Department of Internal Medicine and 
Gastroenterology, ALMAS Hospital, Kottakkal, Malappuram , Kerala, 
India 
12) Nalabothu M, Monigari N, Acharya R. Clinical profile and outcomes of 
rodenticide poisoning in tertiary care hospital. Int J Sci Res Publ 2015; 
5:1-12. 
13) Mishra AK, Devakiruba NS, Jasmine S, Sathyendra S, Zachariah A, 
Iyadurai R. Clinical spectrum of yellow phosphorous  poisoning in a 
85 
 
tertiary care centre in South India: A case series. Trop Doct 2016. pii: 
0049475516668986. 
14) BY Wan Zainal Azman Wan Abdulla General classification of  
pesticides: rodenticides 
15) M.G. Rajanandh and S. Santhosh Retrospective Assessment of Poisoning 
Cases in a Multi Specialty Hospital in Tamilnadu 
16) William Bernal, M.D., and Julia Wendon, M.B., Ch.B. Acute Liver 
Failure N Engl J Med 2013; 369:2525-253. December 26, 2013DOI: 
10.1056/NEJMra1208937 
17) William M. Lee, Jules L. Dienstag Toxic and Drug-Induced Hepatitis 
Harrison's  principles of internal medicine 19 th edition. 
18) Shannan R. Tujios & William M. Lee acute liver Failure  SHERLOCK’S 
DISEASES OF THE LIVER AND BILIARY SYSTEM  University of 
Texas Southwestern   Medical Center, Dallas, TX, USA 
 
 
 
 
 
 
 
86 
 
 
 
 
PROFORMA 
 
 
 
 
87 
 
PROFORMA 
Name   : 
Age / Sex  : 
Occupation  : 
Presenting complaints  
• Time of Consumption  
• Time of Arriving at Hospital 
• Any prior treatment before admission 
• Delay of stomach wash. 
• Amount of poison consumed 
• Time of initiation of NAC. 
Past History   
H/o DM, HT, CKD, CVD, DRUG INTAKE, CAD, Thyroid disorders, Alcohol 
intake 
Clinical Examination: 
General Examination: 
 Consciousness,  
 Pallor,  Jaundice,  
 Clubbing,  
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 Lymphadenopathy,  
 Hydration status 
Vitals: 
 PR 
 BP 
 RR 
 SpO2 
 Urine output 
Systemic examination: 
 
CVS   : 
 
RS   : 
 
ABDOMEN  : 
 CNS   : 
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Laboratory investigations: 
a) Complete blood count, 
b) Liver function test, 
c) Renal function test, 
d) Urine routine, 
e) Serum electrolyte, 
f) prothrombin time and INR, 
g) Bleeding time ,clotting time, 
h) Arterial blood gas analysis, 
i) Electrocardiogram, 
j) USG abdomen, 
 AUTOPSY FINDINGS 
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LIST OF 
ABBREVIATION 
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LIST OF ABBREVIATION 
 
LFT-liver function test 
AST- Aspartate aminotransferase 
ALT- Alanine aminotransferase 
NAC –N Acetyl cysteine 
YP –Yellow phosphorous 
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MASTER CHART
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LIVER FUNCTION TEST – STUDY GROUP 
 
S.NO. 
STUDY GROUP-SERUM 
BILLIRUBIN LIVER ENZYMES AST/ALT PROTHROMBIN TIME/INR  
  
DAY 
1 
DAY 
3 
DAY 
5 
DAY 
6 
DAY 
7 DAY 1 DAY 3 DAY 5 DAY 6 DAY 7 DAY 1 DAY 3 DAY 5 DAY 6 DAY 7  
                                                     
1 0.9 1.5 1 0.9   46 27 49 32 38 24 35 25     12.1 0.56 39 3.04 11.9 0.52 13 1      
2 7.1 11.2 13.8     353 22 480 156 650 315         24 1.8 37 2.9 41 3.2          
3 1.1 1.5 0.9     48 40 50 39 38 31         20 1.5 14 1.1 13.6 1.1          
4 0.8 1.3 1     28 21 52 30 48 35         13 1 16.5 1.3 15 1.2          
5 0.9 1.7 2.9 2 1.3 36 21 96 58 169 118 105 51 93 53 11 0.8 19 1.5 23 1.8 15 1.2 13 1  
6 8.9 21       540 495 1380 1236             47.1 3.7 >3MIN              
7 1.2 2.9 7.9 4.2 1.9 60 51 196 88 370 213 290 171 160 70 14.5 1.1 21 1.6 33 2.6 21 1.6      
8 1.1 1.8 2.5 1.9 1.3 43 39 131 78 206 139 112 70 93 56 13 1 17 1.3 25 1.9 17 1.3 15 1.2  
9 1 1.2 0.9     31 15 40 27 38 22         15 1.2 14.1 1.1 16.3 1.3          
10 2.9 6.4 10.5     296 108 501 302 753 415         17.7 2.1 75.7 5.9 >3MIN          
11 2.2 2.5 1.2     147 767 130 250 130 134         15 1.2 13 1 16.4 1.3          
12 0.9 1.1 1     35 32 46 34 39 30         13 1 12.1 0.9 14 1.1          
13 0.5 1.8 4.7 8.5   38 15 190 102 440 290 752 495     11 0.8 19 1.5 27 2.1 40 3.1      
14 1 2.7 2.3 1.2   4 29 130 105 112 79 78 41     14 1.1 23 1.8 17 1.3 15 1.2      
15 0.9 1.5 2.1 1.7 1.4 30 12 90 73 196 105 126 70 101 47 13 1.01 18 1.4 23 1.8          
16 1.1 2.5 6.9     45 39 215 173 458 360         14 1.1 22 1.7 37 2.9 41 3.2 49.4 3.9  
17 2.1 3 4.5 5.6 3.1 49 33 137 91 102 64 86 36 90 43 16.5 1.1 18.5 1.4 21 1.6 17 1.3 15 1.2  
18 0.6 2.1 4.5 7.8   49 40 88 28 193 117 370 251     17 1.3 25 1.9 31 2.4 40.5 3.17      
19 1.1 2.2 6.4 7.3   39 98 204 180 615 410 930 1205     16 1.2 32.3 2.5 42.8 3.2 47.5 3.7      
20 13.5 24 26     96 30 209 747 490 936         25.2 1.9 29 2.3 >2MIN          
21 1 2.5 0.9     30 15 22 12 27 20         13 1 15 1.2 13.6 1.1          
22 0.7 1.1       41 18 39 24             14.1 1.1 12 0.9              
23 5.4 11.6 23.9 13 8.1 256 198 34 33 271 499 1255 720 282 232 29.8 2.3 52.5 4.1 21.5 1.7 19.5 1.5 16 1.2  
24 1.3 1.6 1.1     37 27 43 31 34 29         12.9 1 16 1.2 14.3 1.1          
25 0.8 2.9 4.1 1.9 1.4 29 21 265 180 310 205 170 90 112 63 15 1.2 21 1.6 24 1.8 19 1.5 16.2 1.3  
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LIVER FUNCTION TEST – CONTROL GROUP 
 
CONTROL GROUP -SERUM 
BILLIRUBIN LIVER ENZYMES AST/ALT PROTHROMBIN TIME/INR 
  
DAY 
1 
DAY 
3 
DAY 
5 
DAY 
6 
DAY 
7 DAY 1 DAY 3 DAY 5 DAY 6 DAY 7 DAY 1 DAY 3 DAY 5 DAY 6 DAY 7 
            AST ALT AST ALT AST ALT AST ALT AST ALT                     
1 1.2 1 0.8     19 11 34 20 39 24         13.2 1 12 0.9 14 1.1         
2 4.9 11.2 22.9     150 114 458 390 680 513         19 1.5 34.2 2.7 51 4         
3 0.9 1.3 1.1     35 29 43 30 38 28         11 0.9 14.8 1.2 13 1         
4 1.5 8.3 17.1 21   106 81 290 105 513 226 740 515     15.6 1.2 18 1.4 28 2.2         
5 9 15.3       315 191 942 905             25 1.92 41 3.2             
6 0.7 1.1 0.9     30 19 37 29 43 24         14.1 1.1 16 1.2 12 0.9         
7 1.3 2.9 6.1 9.3   58 40 190 114 302 173 349 270     11 0.9 19 1.5 27 2.1 39 3     
8 1.1 3.4 5.7     41 26 208 170 760 492         14 1.1 34 2.6 >2MIN         
9 0.7 1.4 1.1     39 24 46 30 41 37         13.6 1.1 12.4 1 11 0.9         
10 3.2 7.9 13.2     190 103 546 280 1102 780         25.3 2 39 3 >3MIN         
11 0.8 1.7 3.4 7   36 22 93 71 370 246 549 403     11.5 0.9 21 1.6 35 2.7 41 3     
12 1.5 4.1 9.8     63 49 156 94 640 491         16 1.2 34.5 2.7 51 4         
13 0.8 1.1       27 24 38 30             11.5 0.9 12.6 1             
14 1.1 7.8 12.9     41 29 280 215 786 543         13.8 1.1 38 3 49 3.9         
15 4.9 10.6       380 443 785 530             24.4 1.9 >2MIN             
16 1 1.4 2.1 1.7 1 40 39 86 39 64 40 53 31 47 29 12.2 1 16 1.2 14.4 1.1 14 1 14 1 
17 0.7 1.9 5.3 9.1   34 29 108 94 310 290 741 960     13.2 1 17 1.3 38.6 3 57 5     
18 1 0.8       39 32 30 37             12.2 0.9 11 0.8             
19 0.9 7.4 13.8     38 31 406 290 741 590         11 0.9 34 2.6 55 4.3         
20 2.8 6.9 10.5     240 194 506 470 1178 1040         26 2 49.4 3.9 >2MIN         
21 1.3 4.8 9.3     78 65 209 190 650 497         17 1.3 47 3.7 >3MIN         
22 0.6 1.1 1.5 0.9   30 17 49 56 34 37 41 29     13 1 15 1.2 14.6 1.1 14 1     
23 1 3.6 9.4 16   26 21 99 84 340 490 780 746     10 0.8 25 1.9 34 2.6 52 4     
24 8.6 15.8       476 341 965 650             21 1.6 58 4.5             
25 1.3 4.9 7.6 12   41 40 371 315 690 536 1476 1140     15.2 1.2 29 2.3 47 3.7 >2MIN     
95 
 
                                                                          MASTER CHART  -STUDY GROUP 
S.NO. AGE SEX ALCOHOLIC 
AMOUNT OF 
POISON 
CONSUMED IN 
GRAMS 
NAC 
GIVEN 
TIME TO 
NAC 
PRESENCE 
OF 
ICTERUS 
ENCEPHALOPATHY HYPOTENSION OLIGURIA LEUCOPENIA LFT RFT 
RESPONSE 
TO NAC DEATH DISCHARGE 
1 25 F N 0.5 Y A N N N N N N N Y N Y 
2 26 F N 5 Y B Y Y N Y N E E N Y N 
3 17 F N 1 Y A N N N N N N N Y N Y 
4 35 M Y 0.5 Y A N N N N N N N Y N Y 
5 24 F N 2 Y A Y N N N N E N Y N Y 
6 29 F N 15 Y B Y Y Y Y Y E E N Y N 
7 40 M N 3 Y A Y N N N N E N Y N Y 
8 22 F N 2 Y A Y N N N N E N Y N Y 
9 31 F N 0.5 Y B N N N N N N N Y Y N 
10 19 F N 10 Y B Y Y Y Y Y E E N N Y 
11 17 F N 2 Y B Y N N N N E N Y N Y 
12 35 M N 0.5 Y A N N N N N N N Y Y N 
13 20 F N 5 Y B Y Y Y Y N E E N N Y 
14 26 M N 3 Y A Y N N N N E N Y N Y 
15 18 F N 2 Y A Y N N N N E N Y Y N 
16 36 F N 5 Y B Y N Y Y N E E N N Y 
17 25 M N 5 Y B Y N N N N E N Y Y N 
18 19 M N 5 Y A Y Y N N N E N N Y N 
19 41 M Y 5 Y B Y N Y Y N E E N Y N 
20 22 M Y 10 Y B Y Y Y Y Y E E N N Y 
21 17 F N 2 Y A Y N N N N E N Y N Y 
22 23 F N 0.5 Y A N N N N N N N Y N Y 
23 21 M N 5 Y B Y N N N N E N Y N Y 
24 42 F N 1 Y A N N N N N E N Y N Y 
25 33 M N 3 Y A Y N N N N E N Y N Y 
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MASTER CHART   -CONTROL GROUP 
S.
N
O. AGE SEX 
ALCOHO
LIC 
AMOUNT 
OF 
POISON 
CONSUME
D IN 
GRAMS 
NAC 
GIVE
N 
TIME TO 
NAC 
INITIATIO
N 
PRESENC
E OF 
ICTERUS 
ENCEPHALOPAT
HY 
HYPOTENSI
ON 
OLIGURI
A 
LEUCOPE
NIA LFT RFT 
RESPON
SE TO 
NAC DEATH 
DISCHAR
GE 
1 19 F N 0.5 N A N N N N N N N NA N Y 
2 36 M Y 5 N B Y Y Y Y Y E E NA Y N 
3 28 F N 0.5 N A N N N N N N N NA N Y 
4 21 F N 3 N B Y Y Y Y N E E NA Y N 
5 35 F N 10 N B Y Y N N N E N NA Y N 
6 23 M N 0.5 N A N N N N N N N NA N Y 
7 20 M N 2 N B Y Y N N N E N NA Y N 
8 17 F N 2 N B Y Y Y Y Y E E NA Y N 
9 19 M N 0.5 N A N N N N N N N NA N Y 
10 20 F N 1 N B Y Y Y Y Y E E NA Y N 
11 40 F N 2 N A Y N Y Y N E E NA Y N 
12 34 M Y 2 N B Y N Y Y Y E E NA Y N 
13 16 F N 0.5 N A N N N N N N N NA N Y 
14 23 F N 2 N A Y Y N N N E N NA Y N 
15 27 F N 5 N B Y Y Y Y Y E E NA Y N 
16 24 M N 1 N A Y N N N N E N NA N Y 
17 19 F N 2 N A Y Y N N N E N NA Y N 
18 17 F N 0.5 N B N N N N N N N NA N Y 
19 52 M Y 1 N B Y Y Y Y N E E NA Y N 
20 24 F N 5 N B Y Y Y Y Y E E NA Y N 
21 31 F N 3 N B Y Y Y Y Y E E NA Y N 
22 18 M N 1 N A N N N N N N N NA N Y 
23 26 F N 2 N A Y N N N Y E N NA Y N 
24 35 F N 10 N B Y Y Y Y N E E NA Y N 
25 19 F N 2 N B Y N Y Y Y E E NA Y N 
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Y  -YES 
N-NO 
A –TIME TO NAC INITIATION <1 DAY 
B – TIME TO NAC INITIATION >1 DAY 
E – ELEVATED 
NA –NOT APPLICAPLE 
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